Evidence map›Paper›PMID 30668888›Full record

ArticleHuman mutation2019

The N-terminal p.(Ser38Cys) TIMP3 mutation underlying Sorsby fundus dystrophy is a founder mutation disrupting an intramolecular disulfide bond.

Sarah Naessens, Julie De Zaeytijd, Delfien Syx, Roosmarijn E Vandenbroucke, Frédéric Smeets, Caroline Van Cauwenbergh, Bart P Leroy, Frank Peelman, Frauke Coppieters

Open access · hybridAbstract read
In one paragraph

Article in Human mutation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Disease-CausingInternational journal of molecular sciences · 2024
    Article
  2. Review
  3. Article
  4. Hidden Relationships betweenInternational journal of molecular sciences · 2022
    Review
  5. The Role of Vitamin A in Retinal Diseases.International journal of molecular sciences · 2022
    Review
  6. A novelOphthalmic genetics · 2020
    Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Sarah NaessensCenter for Medical Genetics Ghent, Ghent University and Ghent University Hospital, Ghent, Belgium.ORCID 0000-0001-9080-3103
Julie De ZaeytijdDepartment of Ophthalmology, Ghent University Hospital, Ghent, Belgium.ORCID 0000-0003-4035-6389
Delfien SyxCenter for Medical Genetics Ghent, Ghent University and Ghent University Hospital, Ghent, Belgium.ORCID 0000-0001-9421-4496
Roosmarijn E VandenbrouckeVIB Center for Inflammation Research, VIB, Ghent, Belgium.ORCID 0000-0002-8327-620X
Frédéric SmeetsDepartment of Ophthalmology, Ghent University Hospital, Ghent, Belgium.ORCID 0000-0002-7191-1456
Caroline Van CauwenberghCenter for Medical Genetics Ghent, Ghent University and Ghent University Hospital, Ghent, Belgium.ORCID 0000-0002-1948-9091
Bart P LeroyCenter for Medical Genetics Ghent, Ghent University and Ghent University Hospital, Ghent, Belgium.ORCID 0000-0002-9899-2081
Frank PeelmanReceptor Research Laboratories, Cytokine Receptor Lab, VIB-UGent Center for Medical Biotechnology, Ghent, Belgium.ORCID 0000-0001-6852-8731
Frauke CoppietersCenter for Medical Genetics Ghent, Ghent University and Ghent University Hospital, Ghent, Belgium.ORCID 0000-0001-7224-0992
Ghent University Hospital · BEGhent University · BEChildren's Hospital of Philadelphia · US

Funding

FWO
6 · The paper itself

Abstract

Sorsby fundus dystrophy (SFD) is a macular degeneration caused by mutations in TIMP3, the majority of which introduce a novel cysteine. However, the exact molecular mechanisms underlying SFD remain unknown. We aimed to provide novel insights into the functional consequences of a distinct N-terminal mutation. Haplotype reconstruction in three SFD families revealed that the identified c.113C>G, p.(Ser38Cys) mutation is a founder in Belgian and northern French families with a late-onset SFD phenotype. Functional consequences of the p.(Ser38Cys) mutation were investigated by high-resolution Western blot analysis of wild type and mutant TIMP3 using patient fibroblasts and in vitro generated proteins, and by molecular modeling of TIMP3 and its interaction partners. We could not confirm a previous hypothesis on dimerization of mutant TIMP3 proteins. However, we identified aberrant intramolecular disulfide bonding. Our data provide evidence for disruption of the established Cys36-Cys143 disulfide bond and formation of a novel Cys36-Cys38 bond, possibly associated with increased glycosylation of the protein. In conclusion, we propose a novel pathogenetic mechanism underlying the p.(Ser38Cys) TIMP3 founder mutation involving intramolecular disulfide bonding. These results provide new insights into the pathogenesis of SFD and other retinopathies linked to mutations in TIMP3, such as age-related macular degeneration.

Indexed as

Founder EffectMutationProtein Interaction Domains and MotifsAgedDisulfidesFemaleFibroblastsGene Expression RegulationHaplotypesHumansMacular DegenerationMaleMatrix Metalloproteinase 2Molecular WeightPedigreeProtein ConformationDisulfidesMatrix Metalloproteinase 2MMP2 protein, humanTIMP3 protein, humanTissue Inhibitor of Metalloproteinase-3aberrant disulfide bondingdimerizationfounder mutationglycosylationSorsby fundus dystrophyTIMP3

Identifiers

PMID30668888
PMCPMC6594137
OpenAlexW2911358415

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.